Michel G. Khouri
Advanced Heart Failure and Transplant Cardiology | Cardiology
40 Duke Medicine Cir
Durham, NC 27710
Durham, NC 27710
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.
Journal: Journal of the American Heart Association
Published: August 31, 2026
124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.
Journal: JAMA
Published: August 30, 2026
Eplontersen for Transthyretin Amyloid Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 28, 2026
Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM.
Journal: European journal of heart failure
Published: June 15, 2026
Design and rationale of the Research with EVuzamitide to Evaluate for cardiac AmyLoidosis (REVEAL) positron emission tomography study: A study of 124I-evuzamitide to diagnose cardiac amyloidosis.
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: May 21, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.
Journal: JAMA cardiology
Published: March 30, 2026
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.
Journal: European journal of heart failure
Published: March 09, 2026
Cardiac Biomarker Complete Response in Light Chain Amyloidosis: How Much of the Heart Is Captured?
Journal: JACC. CardioOncology
Published: February 19, 2026
Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence.
Journal: Circulation. Cardiovascular imaging
Published: February 12, 2026
Disease-modifying Therapies in Transthyretin Amyloid Cardiomyopathy: What Have We Achieved?
Journal: Journal of cardiac failure
Published: January 26, 2026
Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy?
Journal: Circulation
Published: January 26, 2026
Cardioembolic Stroke in ATTR Amyloidosis: What's Rhythm Got to Do With It?
Journal: Journal of the American College of Cardiology
Published: January 13, 2026
Last Updated: 09/26/2026